Similar articles

• Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

  Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin HB, Hartman R, Gharabawi M. Rösler M, et al. BMJ. 1999 Mar 6;318(7184):633-8. doi: 10.1136/bmj.318.7184.633. BMJ. 1999. PMID: 10066203 Free PMC article. Clinical Trial.
• Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.

  Lamb HM, Goa KL. Lamb HM, et al. Pharmacoeconomics. 2001;19(3):303-18. doi: 10.2165/00019053-200119030-00008. Pharmacoeconomics. 2001. PMID: 11303418 Review.
• Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.

  Modrego PJ, Pina MA, Fayed N, Díaz M. Modrego PJ, et al. CNS Drugs. 2006;20(10):867-77. doi: 10.2165/00023210-200620100-00006. CNS Drugs. 2006. PMID: 16999455 Clinical Trial.
• Effect of rivastigmine on plasma butyrylcholine esterase activity and plasma ghrelin levels in patients with dementia in Alzheimer's disease.

  Kuroda A, Setoguchi M, Uchino Y, Nagata K, Hokonohara D. Kuroda A, et al. Geriatr Gerontol Int. 2018 Jun;18(6):886-891. doi: 10.1111/ggi.13275. Epub 2018 Feb 14. Geriatr Gerontol Int. 2018. PMID: 29441654
• Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia.

  Sadowsky CH, Micca JL, Grossberg GT, Velting DM. Sadowsky CH, et al. Prim Care Companion CNS Disord. 2014 Sep 4;16(5):10.4088/PCC.14r01654. doi: 10.4088/PCC.14r01654. eCollection 2014. Prim Care Companion CNS Disord. 2014. PMID: 25667813 Free PMC article. Review.